Condition: Extensive-stage Small Cell Lung Cancer (ES-SCLC) · Extensive Stage Lung Small Cell Cancer · Extensive-Stage Small-Cell Lung Cancer · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This is a single arm, multi-center clinical trial. The goal of this clinical trial is to evaluate the efficacy, safety and biomarkers of Tafolecimab combined with Sintilimab and Chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). Tafolecimab is a recombinant fully humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK-9), which can reduce low-density lipoprotein-C levels and increase the expression level of major histocompatibility complex class I (MHC-I) on tumor cells. Sintilimab is a fully humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1).
This description comes directly from the study's public registry record.
Yang Xia, MD, PhD · +8618868439669 · yxia@zju.edu.cn
Always discuss trial participation with your own doctor first.
| Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University | Changsha, Hunan, China | Not Yet Recruiting |
| Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science | Jinan, Shandong, China | Recruiting |
| Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences | Hangzhou, Zhejiang, China | Recruiting |
| First Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
| Second Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07061535